Open Access Green as soon as Postprint is submitted to ZB.
EBV induces CNS homing of B cells attracting inflammatory T cells.
Nature 646, 171-179 (2025)
Epidemiological data have identified Epstein-Barr virus (EBV) infection as the main environmental risk factor for multiple sclerosis, the predominant autoimmune disease of the central nervous system (CNS)1. However, how EBV infection initiates multiple sclerosis pathogenesis remains unclear. Here we demonstrate that EBV expands oligoclonal T-bet+CXCR3+ B cells that home to the CNS in humanized mice. Effector memory CD8+ T cells and CD4+ TH1 cells as well as CD4+ TH17 cells co-migrate to the brain of EBV-infected humanized mice. T-bet+CXCR3+ B cells can colonize submeningeal brain regions in the absence of other lymphocytes and attract T cells. Depletion of B cells with rituximab or blocking of CXCR3 significantly decreases lymphocyte infiltration into the CNS. Thus, we suggest that symptomatic primary EBV infection generates B cell subsets that gain access to the CNS, attract T cells and thereby initiate multiple sclerosis.
Impact Factor
Scopus SNIP
Altmetric
48.500
0.000
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Epstein-barr-virus; Multiple-sclerosis; Rituximab; Antibody
Language
english
Publication Year
2025
HGF-reported in Year
2025
ISSN (print) / ISBN
0028-0836
e-ISSN
1476-4687
Journal
Nature
Quellenangaben
Volume: 646,
Issue: 8083,
Pages: 171-179
Publisher
Nature Publishing Group
Publishing Place
London
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-502700-002
Grants
University of Zurich (Forschungskredit)
Cancer Research Switzerland
Swiss MS Society
Swiss State Secretariat for Education, Research and Innovation for EU
Sobek Foundation
Swiss Vaccine Research Institute
Vontobel Foundation
Roche
Swiss National Science Foundation
Cancer Research Switzerland
Swiss MS Society
Swiss State Secretariat for Education, Research and Innovation for EU
Sobek Foundation
Swiss Vaccine Research Institute
Vontobel Foundation
Roche
Swiss National Science Foundation
WOS ID
001545414100001
Scopus ID
105012854420
PubMed ID
40770101
Erfassungsdatum
2025-10-08